French Society of Radiation Oncology Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01348217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

SFRO:French Society of Radiation Oncology

Active Ingredients

Drugs in Phase 3 Trials (3)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Esophageal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3